korrents

What Max Hodak thinks about venture capital

@max-hodak · 40 positions · 0 changes of mind

Co-founder and chief executive of Science, a neurotechnology company whose retinal implant restores sight to blind patients; before founding it he spent five years at Neuralink.

Max Hodak did not write this page.

We collected these quotes from things they published elsewhere, and every quote links to where it was said. They have no account here and have not endorsed this site. Quotes are word for word; the short line under each one is our own restatement, not their wording. Their own site. Is this you? Claim it or ask us to remove it. Or tell us what is wrong here.

2 dated positions, 2026, in their own words. Our reading of what Max Hodak has said — not written or endorsed by them.

2 positions so far — this page is not yet offered to search engines.

  1. Our readingTreating brain-computer interfaces as one investment category is like having a single "drug bet" -- the field is as varied as pharma.

    Their wordsYeah, I mean I think BCI is a category kind of like how pharma is a category. I think sometimes you I I'll talk to VCs and like, "Oh, we have a BCI bet." I'm like, "Do you have a drug bet? You made one bet on a drugs? Like that's that's how you think about the category?"

    ↗From Restoring Sight to Reimagining the Brain, with Max Hodakyoutube.com 5th of 18 in this recording

    Interesting
  2. 13 days earlier

  3. Our readingSome ideas are worth funding with fifty million dollars or with nothing, and never with five million, because underfunding buys you an ambiguous outcome instead of an answer.

    Their wordsthere are definitely some ideas that are worth funding with $50 million or zero dollars, but not $5 million. Um you won't run the experiment. It'll be really frustrating experience. You'll get an ambiguous outcome.

    ↗Max Hodak: Average Is Not Good Enoughyoutube.com 19th of 22 in this recording

    Interesting